![Mervyn Rees Thomas](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Mervyn Rees Thomas
Geen lopende functies
Profiel
Mervyn Rees Thomas is associated with two companies as the founder.
He founded Immunexpress Pty Ltd.
in 2006 and Immunexpress, Inc. in 2010.
At Immunexpress Pty Ltd., he held the title of Director-Bioinformatics & Regulatory Affairs, but he was no longer active in that role.
Eerdere bekende functies van Mervyn Rees Thomas
Bedrijven | Functie | Einde |
---|---|---|
Immunexpress, Inc.
![]() Immunexpress, Inc. Miscellaneous Commercial ServicesCommercial Services Immunexpress, Inc. engages in development of revolutionary molecular diagnostics. The firm's SeptiCyte technology quantifies specific and multiple molecular markers from the patient?s own immune system for earlier detection and severity assessment of sepsis, as well as the better timing of drugs and other therapies. The company was founded by Richard Bruce Brandon, Roslyn Brandon and Mervyn Rees Thomas in and is headquartered in | Oprichter | - |
Immunexpress Pty Ltd.
![]() Immunexpress Pty Ltd. Medical SpecialtiesHealth Technology Immunexpress Pty Ltd. engages in creating molecular diagnostics for sepsis. The company was founded by Roslyn Brandon, Mervyn Rees Thomas and Richard Bruce Brandon and in 2006 and is headquartered in Toowong, Australia. | Oprichter | - |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Bedrijven in privébezit | 2 |
---|---|
Immunexpress Pty Ltd.
![]() Immunexpress Pty Ltd. Medical SpecialtiesHealth Technology Immunexpress Pty Ltd. engages in creating molecular diagnostics for sepsis. The company was founded by Roslyn Brandon, Mervyn Rees Thomas and Richard Bruce Brandon and in 2006 and is headquartered in Toowong, Australia. | Health Technology |
Immunexpress, Inc.
![]() Immunexpress, Inc. Miscellaneous Commercial ServicesCommercial Services Immunexpress, Inc. engages in development of revolutionary molecular diagnostics. The firm's SeptiCyte technology quantifies specific and multiple molecular markers from the patient?s own immune system for earlier detection and severity assessment of sepsis, as well as the better timing of drugs and other therapies. The company was founded by Richard Bruce Brandon, Roslyn Brandon and Mervyn Rees Thomas in and is headquartered in | Commercial Services |